US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Sionna Therapeutics / Equity Capital Markets

<ul>
<li>The current price guidance is pointing to the high-end of the prevailing $16-$18 range with allocations expected to be "cut-back".</li>
<li>This biotech is extremely well-backed with RA Capital entering the IPO as the company's largest shareholder (29.2% pre-IPO stake).</li>
<li>Clinical-Stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients is set to go public on Friday. </li>
</ul>


The current price guidance is pointing to the high-end of the prevailing $16-$18 range with allocations expected to be "cut-back".
This biotech is extremely well-backed with RA Capital entering the IPO as the company's largest shareholder (29.2% pre-IPO stake).
Clinical-Stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients is set to go public on Friday. 


Sionna Therapeutics Inc. (SION): Biotech Guiding to High-End Pricing; Expecting Strong Outcome

<ul>
<li>Biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis filed for IPO.</li>
<li>The terms value the company between $652m-$734m with the $16-$18 price range.</li>
<li>The company's existing shareholders include some of the best pre-IPO names in the biotech sphere.</li>
</ul>


Biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis filed for IPO.
The terms value the company between $652m-$734m with the $16-$18 price range.
The company's existing shareholders include some of the best pre-IPO names in the biotech sphere.


Sionna Therapeutics, Inc. (SION): Phase I Cystic Fibrosis Biotech Sets Terms for IPO

<ul>
<li>Biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis filed for IPO.</li>
<li>Company's NBD1 stabilizers, are both in Phase 1 healthy volunteer trials in Australia to evaluate their PK profile, safety and tolerability.</li>
<li>RA Capital, TPG’s the Rise Fund, Atlas Venture, OrbiMed and Enavate Sciences are all among existing investors.</li>
</ul>


Biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis filed for IPO.
Company's NBD1 stabilizers, are both in Phase 1 healthy volunteer trials in Australia to evaluate their PK profile, safety and tolerability.
RA Capital, TPG’s the Rise Fund, Atlas Venture, OrbiMed and Enavate Sciences are all among existing investors.


Sionna Therapeutics, Inc. (SION): Biotech for Patients with Cystic Fibrosis Filed for IPO

United States

Clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sionna Therapeutics (SION US)

Sionna Therapeutics Inc. (SION): Biotech Guiding to High-End Pricing; Expecting Strong Outcome

Clinical-stage biopharmaceutical company backed by RA Capital set to go public with price guidance at high end of range, allocations expected to...

IPO Boutique

Sionna Therapeutics, Inc. (SION): Phase I Cystic Fibrosis Biotech Sets Terms for IPO

Biopharmaceutical company aiming to transform cystic fibrosis treatment seeks IPO, valued between $652m-$734m with strong pre-IPO investor backing.

IPO Boutique

Sionna Therapeutics, Inc. (SION): Biotech for Patients with Cystic Fibrosis Filed for IPO

Biopharmaceutical company developing new treatment for cystic fibrosis files for IPO, with promising NBD1 stabilizers in Phase 1 trials and...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Sionna Therapeutics Inc. (SION): Biotech Guiding to High-End Pricing; Expecting Strong Outcome

​Clinical-stage biopharmaceutical company backed by RA Capital set to go public with price guidance at high end of range, allocations expected to...

IPO Boutique

Sionna Therapeutics, Inc. (SION): Phase I Cystic Fibrosis Biotech Sets Terms for IPO

​Biopharmaceutical company aiming to transform cystic fibrosis treatment seeks IPO, valued between $652m-$734m with strong pre-IPO investor backing.

IPO Boutique

Sionna Therapeutics, Inc. (SION): Biotech for Patients with Cystic Fibrosis Filed for IPO

​Biopharmaceutical company developing new treatment for cystic fibrosis files for IPO, with promising NBD1 stabilizers in Phase 1 trials and...

IPO Boutique

Clinical-stage biopharmaceutical company backed by RA Capital set to go public with price guidance at high end of range, allocations expected to...

Biopharmaceutical company aiming to transform cystic fibrosis treatment seeks IPO, valued between $652m-$734m with strong pre-IPO investor backing.

Biopharmaceutical company developing new treatment for cystic fibrosis files for IPO, with promising NBD1 stabilizers in Phase 1 trials and...